盐酸硫必利与可乐定透皮贴剂联合治疗儿童抽动障碍的疗效分析

中华养生保健 ›› 2024, Vol. 42 ›› Issue (7): 40-43.

盐酸硫必利与可乐定透皮贴剂联合治疗儿童抽动障碍的疗效分析

罗华荣^*, 叶子珊

深圳市龙岗区第三人民医院全科门诊,广东深圳,518115

出版日期:2024-04-01 发布日期:2024-03-20
通讯作者: ^*罗华荣,E-mail：luohuarong06@163.com。
作者简介:罗华荣（1976—）,男,汉族,籍贯：江西省抚州市,本科,主治医师,研究方向：全科医学。

Analysis for the Combination of Thiamphenicol Hydrochloride and Colistin Transdermal Patch in the Treatment of Tic Disorders

LUO Hua-rong^*, YE Zi-shan

General Clinic, the Third People’s Hospital of Longgang District Shenzhen, Shenzhen Guangdong 518115, China

Online:2024-04-01 Published:2024-03-20

摘要/Abstract

摘要： 目的探讨硫必利联合可乐定透皮贴剂治疗抽动障碍的疗效。方法选取2022年5月—2023年5月深圳市龙岗区第三人民医院收治的共计119例抽动障碍患儿作为研究对象,按照随机数表法分为联合组、硫必利组、可乐定组。联合组41例采用硫必利联合可乐定透皮贴剂治疗,硫必利组39例单一采用口服盐酸硫必利片治疗,可乐定组39例采用单一可乐定透皮贴治疗,三组持续治疗12周。统计并比较三组患儿耶鲁抽动障碍评分（YGTSS）、治疗有效率以及不良反应发生率。结果治疗8周以及12周后,三组患儿的YGTSS评分较治疗前降低,且联合组YGTSS评分低于硫必利组、可乐定组,差异有统计学意义（P<0.05）,硫必利组与可乐定组在治疗8周以及12周后的YGTSS评分比较,差异无统计学意义（P>0.05）。联合组总体有效率稍高于硫必利组、可乐定组,但差异无统计学意义（P>0.05）。三组患儿不良反应发生率比较,差异无统计学意义（P>0.05）,均未发生严重不良反应。结论盐酸硫必利联合可乐定透皮贴片治疗抽动障碍相比单一使用盐酸硫必利或可乐定透皮贴片近期效果更好,相同时间对抽动障碍患儿抽动症状控制效果更优,且联合用药无严重不良反应。

关键词: 抽动障碍, 盐酸硫必利片, 可乐定, 神经疾病

Abstract: Objective To explore the clinical efficacy of thiamphenicol combined with colistin transdermal patch in the treatment of tic disorders. Methods A total of 119 children with tic disorders admitted to the pediatric outpatient clinic of the Third People's Hospital of Longgang from May 2022 to May 2023 were selected as the study subjects, they were randomly divided into three groups. The combined group of 41 cases were treated with thiamphenicol combined with colistin transdermal patch. The thiamphenicol group of 39 cases were treated with oral thiamphenicol hydrochloride tablets. The colistin group of 39 cases were treated with a single colistin transdermal patch. Ttreatment of the three groups lasted 8 weeks. The Yale Grade Tourette Syndrome Score (YGTSS), treatment efficiency, and dangerous events were recorded through the whole study. Results The YGTSS scores of children in the three groups were lower at 8 w and 12 w after treatment compared with those before treatment, and the YGTSS scores of the combined group were lower compared with those of the other two single-administration groups (P<0.05), and the differences in YGTSS scores of the single thiabendazole group compared with those of the single colestipol group were not statistically significant at 8w and 12w after treatment (P>0.05). The total effective rate of the three groups were 87.8% in the combined group, 82.05% in the tiapride group and 84.62% in the clonidine group (P>0.05). The incidence rates of adverse reactions in the three groups were 17.07% in the combined group, 12.82% in the tiapride group, and 10.26 % in the clonidine group, 12.82% and 10.26% (P>0.05), and among the adverse events there were no critical serious events. Conclusion Thiopride hydrochloride, colistin transdermal patch, and the combination of treatment modalities have more objective efficacy in the therapeutic effect of tic disorders, and no critical adverse events and dangerous situation, but by combining thiopride hydrochloride and colistin treatment modalities can be better control of children's tic conditions within the same period of time, and the therapeutic effect is more accurate, and it is worth to be popularized.

Key words: tic disorders, tiapride hydrochloride tablets, colistin transdermal patch, neurological disease

中图分类号:

R741

罗华荣, 叶子珊. 盐酸硫必利与可乐定透皮贴剂联合治疗儿童抽动障碍的疗效分析[J]. 中华养生保健, 2024, 42(7): 40-43.

LUO Hua-rong, YE Zi-shan. Analysis for the Combination of Thiamphenicol Hydrochloride and Colistin Transdermal Patch in the Treatment of Tic Disorders[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(7): 40-43.

参考文献

[1] 潘雪芸,王燕.抽动障碍病因研究现状[J].实用医学研究,2022,4(5):95-97.
[2] 林宁安,朱哲,应勤滨,等.影响儿童发生抽动障碍的相关危险因素调查[J].中国妇幼保健,2022,37(11):2058-2060.
[3] 姜妍琳,张蔷,翟睿,等.中国儿童抽动障碍患病率及危险因素系统评价[J].中国儿童保健杂志,2023,31(6):661-667.
[4] 程晓,杨春松,张川,等.抽动障碍患儿药物治疗依从性的系统评价[J].中国循证医学杂志,2021,21(5):586-592.
[5] 辛莹莹,孙丹,刘智胜.Tourette综合征及其他抽动障碍心理干预的欧洲临床指南(2021版)解读[J].中华实用儿科临床杂志,2022,37(8):596-600.
[6] 美国精神医学学会,张道龙.精神障碍诊断与统计手册[M].北京:北京大学出版社,2014:77-82.
[7] 杨春松,张伶俐,俞丹,等.硫必利联合可乐定对比硫必利、可乐定单药用于儿童抽动障碍有效性和安全性的队列研究[J].中国药房,2021,32(20):2514-2519.
[8] LECKMAN J F, RIDDLE M A, HARDIN M T, et al.The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity[J]. J Am Acad Child Adolesc Psychiatry,1989,28(4):566-573.
[9] 姚兰芳,刘自强,朱翠琼.盐酸硫必利片联合中医疗法对小儿抽动症治疗效果及认知功能的影响[J].中国药物经济学,2022,17(11):83-86.
[10] 顾水琴. 可乐定透皮贴片和盐酸硫必利治疗慢性抽动障碍的疗效[J].系统医学,2021,6(23):117-120.
[11] JOSEPH J, MAKOTO M, ANDREA D, et al.Inhibitory control in children with tic disorder: aberrant fronto-parietal network activity and connectivity[J]. Brain Commun,2021,3(2):1-15.
[12] 张娟,刘文龙,王真真.盐酸硫必利与可乐定透皮贴治疗抽动障碍临床疗效的比较研究[J].临床合理用药杂志,2019,12(30):77-78.
[13] 李同. 盐酸硫必利、安定、苯巴比妥术前给药的临床观察[J].中国医药指南,2021,19(36):82-84.
[14] 宋好鑫,黄宗瑶,杨春松,等.可乐定透皮贴治疗儿童抽动障碍的有效性与安全性的Meta分析[J].中国药房,2019,30(1):125-130.
[15] 李俭俭,郑华城,刘振奎.可乐定透皮贴剂联合盐酸硫必利治疗儿童抽动障碍的疗效分析[J].脑与神经疾病杂志,2017,25(6):376-378.